Cell Therapeutics (CTIC) 2.98 $CTIC
Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.
Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.
Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:
Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.
Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....
Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).
Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.
Zack's Research Initiates Coverage on Theralase With a Price Target of $1.00
ACCESSWIRE - Tue May 20, 9:22AM CDT
Theralase Lights Up Cancer Therapeutics
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -
PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.
Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.
Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:
Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.
Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....
Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).
Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.
Zack's Research Initiates Coverage on Theralase With a Price Target of $1.00
ACCESSWIRE - Tue May 20, 9:22AM CDT
Theralase Lights Up Cancer Therapeutics
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -
PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
